Patients with end-stage renal disease (ESRD) commonly present both anorexia (defined as reduced apetite) and a catabolic state leading to loss of protein from skeletal muscle and other tissues. Additionally, these patients carry an inflammatory burden, which may play a pivotal role in the evolution of not only the observed cachexia, but also in the massive increase in relative risk of cardiovascular disease (CVD) in this population. Evidence suggests that a facilitative interaction between pro-inflammatory cytokines and other factors, including central nervous system regulation of appetite, co-morbidies, acidosis, anaemia and hormonal derangements combine to produce both anorexia and cachexia in this patient group. So far, interventional therapies have failed to significantly alleviate the cachexic state in ESRD, presumably because of the need to attack other causative factors. Therefore, new treatment strategies such as multiple appetite stimulants, various "anti-inflammatory diets" and new potentially useful anti-inflammatory pharmacological agents should be tested alone or in combination to evaluate if these new therapeutic modalities could improve the poor outcome of ESRD patients. As the etiology of cachexia in ESRD is multifactorial, we propose that its treatment should comprise a number of concomitant therapies to provide an integrated strategy aiming to reverse this devastating complication.
INTRODUCTION
Protein-energy malnutrition is a common feature in endstage renal disease (ESRD) patients [1] , which becomes even more common after patients start on either peritoneal dialysis (PD) [2] or haemodialysis (HD) [3] . Although it is well established that malnutrition is one important predictor of survival in ESRD patients [2, 3] , less is known about malnutrition and its impact on clinical outcomes in patients with a modest degree of chronic kidney disease. As noted by Mitch [4] the use of the word malnutrition has previously often been used incorrectly in the renal literature. Literally, the word "malnutrition", derived from Latin malus, means "not correctly nourished" and includes any disorder of nutrition (i.e. both under-and overnutrition). In the following text, we will therefore refer to cachexia, defined as a state of undernutrition deriving from both anorexia, i.e. insufficient food intake, and low serum protein levels and the loss of muscle mass as the result of a catabolic state. All of these factors occur in the ESRD patient, usually as the consequence of a number of interrelated mechanisms stimulated by renal insufficiency. Indeed, the aetiology of the cachexia in ESRD is very complex and may include numerous factors including loss of appetite, delayed gastric emptying, impaired protein assimilation, hormonal derangements, inadequate control of acidosis, co-morbidity, inflammation, depression and other psychosocial factors [4] . Therefore, it is not likely that wasting in ESRD can be adequately treated by only one single therapy; instead we propose the concept of an integrated therapy of wasting consisting of both dietary and pharmacological components. 
PREVALENCE OF CACHEXIA IN THE ESRD POPULATION
Assessment and monitoring of nutritional status are essential to prevent, diagnose and treat uremic cachexia, anorexia and catabolism [5] . Common signs of cachexia in ESRD patients ( Table 1 ) include reduced muscle mass as assessed by anthropometric methods as well as low serum concentrations of albumin, transferrin, prealbumin and other
Table 1. Markers of Malnutrition and Cachexia in ESRD
Patients § Body weight (% relative body weight, % preuremic body weight) § Body mass index § Visceral proteins (serum protein, albumin, prealbumin, transferin and IGF-1) § Subjective global assessment of nutritional status § Handgrip strength § Antropometrics (skinfold thickness and midarm muscle circumference § Lean body mass (estimated by DEXA, bioimpedance or creatinine kinetics) § Body fat mass (estimated by DEXA or CT) § Total body nitrogen and total body potassium § Essential (low in ESRD) and non-essential (high in ESRD) plasma amino acids § Protein intake estimated by nPNA a a nPNA, protein equivalent of nitrogen appearance in urine and dialysate, normalized to actual or desirable body weight.
liver-derived proteins. Subjective global assessment of nutritional status (SGA) [6] , a clinical scoring system taking into account both subjective and objective factors, is the most commonly used methods to identify cachexia in scientific studies.
Several reports have shown a high prevalence (about 20-60%) of cachexia in ESRD patients, both before and after initiation of dialysis therapy [2, 7, 8] . Whereas, the prevalence and severity of both anorexia and catabolism is clearly related to residual renal function [9] , the choice of dialysis modality does not seem to play a major role. A few studies [10, 11] have compared the prevalence of malnutrition in PD and HD patients, and in most of these studies, no major differences were found. A common finding is that there is a larger gain in body fat in PD compared with HD patients [8] , most likely due to the impact of glucose absorption from the dialysate, and the absence of the intermittent catabolic stimulus associated with the HD procedure. In addition, part of the reported weight gain may be due to increased body water associated with poor control of fluid balance.
THE IMPACT OF DIALYSIS THERAPY
Before initiation of dialysis therapy, ESRD patients usually spontaneously decrease their protein intake as a consequence of declining renal function and uremic symptoms [12] , or because they are prescribed low protein diets to avoid these symptoms. Also, some of the many drugs used by ESRD patients may worsen anorexia. In addition, underlying or intercurrent diseases, such as diabetes mellitus (DM), cardiovascular disease (CVD), infections, various complications of dialysis therapy as well as medications, in particular corticosteroid therapy, and not least a state of chronic systemic inflammation, may all contribute to anorexia in this patient group [13] .
Once dialysis therapy begins, uremic symptoms are usually alleviated, and the diet restrictions relaxed. This leads to an improved appetite in most patients [8] , while it is less common to see a reversal of the objective signs of cachexia. Indeed, additional metabolic and nutritional problems may be induced by the dialysis procedure, including losses of proteins, amino acids, water-soluble vitamins and other essential small molecular solutes into the dialysate, as well as catabolism and suppression of appetite mediated by systemic inflammation due to bioincompatability of the therapy or, in PD, from dialysate glucose absorption and abdominal discomfort induced by the treatment.
As the dialysis dose was increased during the 1980s and 1990s, additional changes in Kt/V resulted in only marginal, or not even significant, reductions in patient mortality, as recently shown in the HEMO [14] and ADEMEX [15] studies. Thus, factors other than dialysis dose, such as cardiovascular complications, inflammation and catabolism appear to be more important determinants of patient cachexia and survival in ESRD. In fact, most premature deaths in ESRD patients are now thought to be associated with the presence of a Malnutrition/wasting, Inflammation and Atherosclerosis (MIA) syndrome. This is an important consequence of the uremic syndrome as well as both a cause and a consequence of the coexisting co-morbidities such as diabetes mellitus and left ventricle hypertrophy of the heart [13, 16] .
CACHEXIA, INFLAMMATION AND CARDIOVAS-CULAR DISEASE
Low-grade chronic and systemic inflammation, with increased circulating levels of C-reactive protein (CRP) and pro-inflammatory cytokines, such as tumour necrosis factor (TNF)-α and interleukin (IL)-6, has been proposed to be one of the most important contributors to cachexia in ESRD patients [17] . Moreover, since the idea that inflammation plays a key role in the atherogenic process has received much attention in non-renal patients [18] , it has been speculated that inflammation also contributes to increased CVD and thus links these two important causes of morbidity in dialysis patients [19] .
Although cachexia, since the 1980s, and systemic inflammation, since the 1990s, have both been reported to be strong predictors of mortality in dialysis patients, they usually do not appear as documented direct causes of mortality. Instead, CVD is by far the most common documented cause of mortality in the dialysis population, while malnutrition is a reported direct cause of less than 5% of deaths [20] . The causes of CVD in ESRD patients are multifactorial including both traditional Framingham risk factors, such as age, smoking, DM and hypertension, as well as emerging non-traditional risk factors, such as inflammation, oxidative stress and vascular calcification. Over the last several years, the role of inflammation in the pathogenesis of atherosclerosis has received much attention [18] , and it is possible that inflammation may contribute to increased cardiovascular morbidity and mortality also in dialysis patients. In ESRD, although total protein metabolism is not changed, a shift is observed towards synthesis of acute phase and immunocompetent proteins, at the expense of muscle anabolism [21] . Indeed, pro-inflammatory cytokine levels have recently been shown to predict cachexia and mortality in ESRD patients with or without ongoing dialysis treatment [19, 22] . Moreover, both cachexia and inflammation are strongly associated with CVD, resulting in higher mortality rates in malnourished patients [16] . Indeed, cachexia (evaluated by SGA) is more common in patients with clinical CVD [17] and Beddhu et al. [23] have demonstrated a significantly greater prevalence of coronary artery disease in dialysis patients with low S-albumin. However, in another study by Beddhu et al. [24] , he found no association between malnutrition (defined BMI <18.5 kg/m 2 and by a low urinary creatinine excretion) and acute coronary syndromes in a large group of dialysis patients. Although BMI may not be a precise marker of nutritional status it is clear that further studies are needed to resolve the putative associations between atherosclerotic cardiovascular disease and anorexia and protein-energy undernutrition on the one hand and inflammatory-associated muscle catabolism on the other.
INFLAMMATION AS A CAUSE OF ANOREXIA, CATABOLISM AND CACHEXIA
In patients who have signs of systemic inflammation, symptoms such as anorexia, loss of body weight, malaise, fatigue and depression are commonly observed. As weight loss is such a common feature of many inflammatory disorders, it has been suggested that subclinical inflammation is a principal component of the pathophysiology of cachexia by causing both anorexia through central mechanisms [25, 26] as well as increased muscle catabolism [27] . It is therefore not surprising that pro-inflammatory cytokines have been shown to have significant effects on wasting and sickness behaviours in dialysis patients [26, 28] and may play a central role in the development and maintenance of the MIA syndrome [29, 30] .
TNF-α has been recognized as the prototype of an anorectic cytokine [28] . Important mechanisms by which elevated levels of TNF-α may mediate catabolism include increased protein hydrolysis coupled with local insulin resistance [31] . TNF-α has also been shown to activate the transcription factor NF-κB to suppress MyoD mRNA and disrupt skeletal muscle differentiation and repair of damaged muscle tissue [32] . A decrease in muscle mass may also be caused by activation of the ubiquitin-proteasome proteolytic system, which accelerates degradation of muscle protein [33] . Since TNF-α increases ubiquitin gene expression in skeletal muscle [34] , it is possible that this cytokine causes muscle wasting by stimulating protein catabolism via the ubiquitin proteosome pathway [35] . It has also been reported that TNF-α increases the rate of DNA fragmentation in cancer cachexia promoting apoptosis [36] . Indeed, cachexia is usually associated with elevated concentrations of TNF-α in older patients without renal disease [37] . In dialysis patients, elevated TNF-α levels has been reported to be associated with anorexia [25] . Furthermore, Grunfeld et al. [38] found that administration of TNF-α resulted in an increase in leptin mRNA levels in hamsters and noted a strong inverse correlation between leptin mRNA level and subsequent food intake.
IL-6 is another pro-inflammatory cytokine proposed to play an important role in the muscle catabolism which occurs with normal aging [39] . It has been suggested that the process of age-related muscle loss (sarcopenia) is related to loss of sex hormones (particularly testosterone) that act to suppress IL-6 expression [40] . Indeed, IL-6 has been shown to stimulate the breakdown of muscle protein [41] and promote cancer-related wasting [42] while the administration of IL-6 receptor antibody has been shown to inhibit muscle atrophy that occurs in IL-6 transgenic mice [43] . Since IL-6 also inhibits the secretion of insulin-like growth factor (IGF-1), reduced IGF-1 signaling may be yet another reason for IL-6-associated muscle atrophy [44] . The close association between IL-6 and muscle wasting (evaluated by thigh muscle area) in HD patients [45] provides compelling evidence that this cytokine may be catabolic also in this patient group. Finally, since intra-cerebroventricular injection of IL-6 increases energy expenditure and decreases body fat in rodents, IL-6 may play an important role in appetite and body weight control mediated by the central nervous system [46] .
Recently, the role of elevated circulating levels of cytokines such as leptin on signaling through the central melanocortin system has been proven to be of importance in causing anorexia in ESRD [26] . Also, impaired protein assimilation may contribute to cachexia in renal disease. Indeed, a recent study [47] indicated both that protein uptake from the gut is increased in ESRD, and that the severity of this decrease is associated with the severity of MIA present. Among the large number of other cytokines that may have nutritional impact, IL-15 has recently attracted much interest as it exerts important effects in skeletal muscle where it behaves as an anabolic cytokine both in vitro [48] and in vivo [49] and favours muscle fibre hypertrophy. This cytokine exerts its effects in muscle cells by both decreasing the rate of protein degradation and increasing the rate of proliferation. This distinct mode of IL-15 action suggests that it may be of potential usefulness in the treatment of wasting disorders, and early trials in rodents [50, 51] have been encouraging, attenuating muscle protein breakdown and increasing muscle mass. Therefore, studies on the effects of IL-15 administration are warranted in experimental renal failure models.
TREATING CACHEXIA IN ESRD
The strong association between inflammation and nutritional status is of importance when considering strategies to treat or prevent cachexia in dialysis patients. Indeed, if the cause of malnutrition was only anorexia, ie. inadequate nutritional intake was the predominant cause, one would expect that nutritional supplementation alone would be effective in restoring nutritional deficits. However, as oral nutritional supplements or intradialytic supplementation have proved either only partial effective [52] , or totally ineffectual [53] , in the repair of nutritional status in the majority of ESRD patients, dialysis patients are not likely to be able to feed themselves out of a malnourished state. Instead, new therapies designed to help these patients must also be used to address the catabolic state.
Inflammation appears not only to decrease muscle protein synthesis, but may also raise resting energy expenditure and protein catabolic rate -changes that will promote a negative protein and energy balance -as well as decrease protein assimilation from the gut. Thus, it is unlikely that we can reverse the catabolic process unless we also treat inflammation and its' associated co-morbidities. Indeed, we believe that inflammation-driven hypercatabolism and failure to deposit nutrients may be the main reason for a poor nutritional status in uremic patients. It is thus interesting that most studies done on nutritional supplementation in ESRD patients used a low S-albumin to identify patients considered malnourished. As S-albumin is much more a marker of inflammation than of nutrition, it is not surprising that the results often could not demonstrate any beneficial effects on nutritional status. Clearly, in the clinical setting anorexia, catabolism, cachexia and inflammation occur together and are difficult to isolate.
THE ROLE OF APPETITE STIMULANTS IN ESRD
Anorexia is a common phenomenon in ESRD patients that is associated with higher levels of pro-inflammatory cytokines, greater hospitalization rates and poor clinical outcomes [54] . Thus, a simple inquiry about appetite may yield important information about the future risk of poor outcome in the ESRD patient. The are several different mechanisms contributing to anorexia in dialysis patients, including inadequate dialysis, delayed gastric emptying, elevated levels of anorectic substances, like leptin and proinflammatory cytokines, as well as effects of the haemodialysis procedure and the intraperitoneal infusion of dialysis fluid in PD patients [55] . Although some of these causes of anorexia can be treated through measures such as an increased dialysis dose in underdialysed patients and decreased intraperitoneal volume in PD patients with local symptoms, it is evident that these measures not always are effective. Therefore, the use of appetite stimulants is a tempting part of an integrated therapy against malnutrition in dialysis patients. Examples of pharmacological agents that may stimulate appetite are given in Table 2 . Unfortunately, most appetite stimulatory drugs available are relatively ineffective and they have not been systematically tested in dialysis patients. • Nuts and seeds (γ-tocopherol)
• Moderate alcohol consumption (ethanol and flavonoids)
• Diets rich in anti-oxidants (living food, antocyanins)
• Probiotics (living microorganisms)
• Diets low in advanced glycation end-products
Ghrelin is an appetite-stimulating gut hormone that in at least one randomized, placebo-controlled trial [56] has been shown to be able to attenuate short-term food intake in dialysis patients with mild to moderate malnutrition.
Megesterol acetate, a steroid like progestagen used for treatment of breast cancer, showed increased appetite and weight gain as an unexpected side effect [57] . Subsequently, the orexigenic and weight gaining effects of megesterol acetate have been attributed to its anti-cytokine effects via reduced levels of IL-6 and TNA-α [58] . Megesterol acetate is the most extensively studied appetite stimulant and is widely used in cancer and AIDS-patients [59] but currently not in ESRD. However, serious side effects mean that the treatment may be risky and must be monitored closely [60] .
Cannabinoids, such as dronabinol (∂-9 tetrahydrocannabiol), have been reported to increase appetite and weight gain. In HIV and Alzheimer disease patients, dronabinol may reduce cachexia and induce weight gain [61] . The possible mechanisms of action include interactions with endorphin receptors, inhibition of prostaglandin synthesis and IL-1 secretion [59] . Although the drug is eliminated primarily through the biliary system, the therapeutic window is narrow and several CNS side effects have been reported, including somnolence, dizziness, paranoid reactions and other mental effects [62] . A comparison of dronabinol against megesterol acetate in a group of patients with advanced cancer found that megesterol acetate had a significantly better effect on appetite and weight gain [63] . To the best of our knowledge, no studies have been performed to study the putative appetite stimulating effects of cannaboids in ESRD patients.
Several studies have demonstrated that corticosteroids increase appetite and well being in cancer patients although a long lasting weight gain is often not observed [64] . Since the effect is short lasting and the side effects (including the stimulation of muscle proteolysis through the ubiquitinproteasome pathway) may be serious, however, corticosteroids have no primary role in the treatment of malnutrition in dialysis patients. Cyproheptadine, an antihistamine with serotonin antagonist properties has mainly been used for the treatment of cancer-induced weight loss, and in anorexia nervosa, but the effects have been questionable [62] . Other possible anti-anorectic drugs, such as thalidomide (because of its effect on TNF-α) and melatonin (because of its effect on muscle metabolism), are presently reaching the clinical trial stage [65] .
NUTRITIONAL SUPPLEMENTS WITH PHARMA-COLOGICAL EFFECTS
Based on epidemiological studies in both renal and nonrenal populations, it is obvious that important differences regarding the prevalence and outcome of wasting, inflammation and atherosclerosis exist in different parts of the world [66] . In this respect it is of interest that although CVD is the leading cause of death in dialysis patients in Asian countries, the prevalence of inflammation [67, 68] and vascular disease [69] are substantially lower in Asian countries than in Western countries. The observation that Asian patients who receive dialysis in the United States have a markedly lower adjusted relative death risk than Caucasians [69] implies that factors unrelated to dialysis treatment characteristics, such as dietary and/or cultural habits, may contribute to the observed differences ( Table 1) . Thus, recent interest has focused on the putative antiinflammatory effects of various dietary components of the diet consumed in many parts of Asia.
In general, the population in Southeast Asia, China and Japan consumes a substantial amount of fish and soy, resulting in a lower fat content and a higher fibre diet than the typical Western diet. Soybeans are a unique source of the phytoestrogens (natural compunds that mimic some of the effects of estrogen in vivo) and in the Japanese population the phytoestrogen concentration is markedly higher than in other populations [70] . Phytoestrogens modulate the intranuclear estrogen receptor system, and thus have numerous biological functions, such as modulation of cell growth-proliferation, inflammation and oxidative stress. The phytoestrogen genistein is effective in blocking inflammatory gene expression [71] , but no randomized, controlled studies have been performed in humans to evaluate either an anti-inflammatory effect or a hypothetical effect on cachexia. Based on these findings, prospective studies on the impact of a high-soy diet on both the prevalence of MIA and outcome in ESRD patients are warranted [72] .
Other components of the East-Asian diet that may contribute to a lower risk of inflammation and CVD include higher dietary fibre content as well as increased fish consumption. The importance of dietary fibres is underscored by a recent evaluation of 4,900 participants of the 1999-2000 NHANES demonstrating that subjects in the 3rd and 4th highest quartiles of fibre consumption had a lower risk of elevated CRP [73] . The anti-inflammatory and cardioprotective effects of the omega-3 fatty acids of fish oil, mainly eicosapentaenoic acid, are well recognized. For example, dietary fish oil decreases CRP and IL-6 levels in non-renal subjects [74] . In addition, Kutner et al. [75] found that dialysis patients who reported fish consumption were 50% less likely to die during the observation period. Therefore, the potential beneficial effects of this culinary form of anti-cytokine therapy certainly merit further investigation.
Lifestyle modification may be another important component in normalizing the dysregulated cytokine system activity in ESRD patients [76] . A recent epidemiological study [77] showed that frequent exercise of up to 4 to 5 times/wk with was associated with improved survival. Also, a 2-year multidisciplinary program that included both consumption of a Mediterranean-style diet and increased physical activity resulted in a reduction in IL-6, IL-18 and CRP levels in obese women [78] . Among other nutritional factors that may affect inflammation, moderate alcohol consumption should definitely be mentioned as it has been shown to be associated with all-cause mortality in a J-or Ushaped manner in the general population. It should be noted that although changes in lipids, such as increased HDLcholesterol and apolipoprotein A-l, and a favourable haemostatic profile may contribute to the favourable effects of a moderate intake of alcohol, anti-inflammatory effects may also be important [79] .
Perhaps one of the most intriguing findings in nutritional epidemiology over the last couple of years has been the observation that increased seed, nut and berry consumption seems to protect against coronary artery disease [80] . In general, nuts and seeds constitute an important part of plantbased diets, such as the Mediterranean and most Asian diets. Furthermore, nuts and seeds are a major source of gammatocopherol [81] , an anti-inflammatory and anti-oxidant compound believed to modulate the risks for aging-related diseases such as cancer and heart disease [82] . Meanwhile, blue or red fruits and berries contain high levels of antocyanins, which have been proven to exert powerful antioxidative effects in vitro. Increased oxidative stress is a common feature of ESRD that seems to be strongly associated with both MIA features [83] and outcome [84] . Plants are rich natural sources not only of antioxidants but also of other nutrients. For example, a number of interventions and cross sectional studies have been performed on subjects consuming an uncooked vegan diet, so called "living food" (such as berries, fruits, vegetables and roots, nuts, germinated seeds and sprouts, i.e. food sources rich in carotenoids, vitamins C and E) in rheumatoid arthritis (RA) patients, in which inflammation is a hallmark, with positive subjective and objective results [85] . Such studies have yet to be performed in the renal population, however two recent studies using the anti-oxidant compound N-acetylcysteine have shown positive impact on both inflammation and CVDmortality in HD patients [86] and in a mouse model [87] .
Advanced glycation end-products (AGEs), the result of the nonenzymatic reaction of reducing sugars with proteins, lipids and nucleic acids, are usually markedly elevated in ESRD patients. It has been proposed that AGEs promote atherosclerosis through interaction with endothelial receptors [88] . Although reduced renal clearance and increased oxidative stress may be the most important causes of elevated AGEs in ESRD patients, diet may be an important source of highly reactive AGEs. As correlations have been found between one form of AGE, pentosidine, and CRP in both renal [89] and non-renal [90] patients, it has been suggested that AGEs can trigger an inflammatory response [91] . Uribarri et al. [92] have shown that dietary glycotoxins contribute to significantly elevated AGE levels in ESRD patients. Further studies are thus warranted to elucidate if dietary restrictions of the intake of AGE may reduce both excess toxic AGE and inflammation in this patient group. Importantly, a reduction in dietary AGE content can be obtained safely without compromising the content of vital nutrients, such as dietary protein, fat, and carbohydrates [93] . It may also be possible to use drug therapy to induce the breakdown of pre-existing AGEs. One example of such a drug, which is presently being evaluated in clinical trials, is ALT-711 [94] . This cross-linked breaker also has beneficial effects on putative mediators of renal injury, such as prosclerotic cytokines and oxidative stress [95] , that might be beneficial for ESRD patients.
PHARMACOLOGICAL THERAPY DIRECTED AGAINST INFLAMMATION
Given the strongly documented associations between pro-inflammatory cytokines and complications common in ESRD, such as CVD and cachexia, various pharmacological and anti-cytokine treatment strategies have been proposed for these patients ( Table 3) . In this respect it is notable that several commonly used drugs in clinical practice, such as statins and ACE-inhibitors (ACEI), possess significant anticachectic and anti-inflammatory effects.
Conventional Anti-Inflammatory Drugs
It is now evident that statins not only inhibit cholesterol synthesis but also have "pleiotropic effects", such as antiinflammatory actions [96] . Randomization to pravastatin after myocardial infarction resulted in significant reductions in CRP [97] and one study showed that atorvastatin inhibits IL-6 secretion in adipocytes [98] . Part of this immunoprotective effect may be due to promotion of Th2 development [99] and this may have a therapeutical potential not only in atherosclerosis but also in inflammatory and wasting disorders [100] . Indeed, two studies have demonstrated that statins, in addition to its lipid-lowering effect, also had an anti-inflammatory effect in HD patients [101, 102] . However, although simvastatin reduced the inflammatory response, it did not prevent muscle wasting in an experimental model of cancer cachexia [103] . Paradoxically, since lipoproteins isolated from normal human plasma can bind and neutralize bacterial lipopolysaccharide [104] , a cholesterol-lowering may represent a disadvantage in wasted ESRD patients. In fact, it has been speculated that "non-lipid lowering statins" may be as effective and even more beneficial than "lipid-lowering statins" in wasted and Compounds that may stimulate appetite.
Drugs that may have secondary anti-cytokine effects.
• HMG-CoA reductase inhibitors
inflamed patients [105] . This hypothesis has been challenged by the observation by Liu et al. [106] that the inverse association between total cholesterol with mortality in dialysis patients is related to the cholesterol-lowering effect of systemic inflammation and wasting. We thus now wait for the several large, ongoing, randomized clinical trials in the renal population to be published in order to learn more about this interesting therapy option.
Another commonly used drug with hypothetical antiinflammatory properties in vivo are the ACEI [107] . Brull et al. [108] have noted that ACEI treatment was associated with a reduction in IL-6 in response to coronary artery graft surgery while we have found lower plasma levels of TNF-α in ESRD patients treated by ACEI [109] . A recent study of 1,920 patients with congestive heart failure (CHF) from the SOLVD trial demonstrated that treatment with an ACEI reduced the risk of weight loss [110] , supporting the hypothesis of strong relationships between cachexia, the renin-angiotensin system and inflammation. Since the use of ACEI is independently associated also with a decreased rate of decline in residual renal function in dialysis patients [111] , it is furthermore not surprising that ACEI improves the prognosis of renal patients [112] , however to which extent this is due to decreased malnutrition is not clear.
Several other drugs also have anti-inflammatory effects. Peroxisome proliferators-activated receptor (PPAR-χ activators, i.e. glitazones) have also been shown to inhibit the activation of inflammatory response genes, and promote a deviation of the immune system away from Th1 toward Th2 cytokine production [113, 114] . Recently, the calciumfree phosphate binder sevelamer has been shown to have both anti-inflammatory and LDL-lowering effects [115] , and it has been hypothesized that these effects are the main cause of the reduced CVD and mortality observed in clinical trials with this drug [116] .
Anabolic Drugs
Anabolic androgenic steroids, such as testosterone, nandrolone, oxandrolone and stanozol, include a diverse family of steroidal hormones and synthetic hormone derivates, which have anabolic and anti-catabolic effects. These drugs have been studied in a number of settings of catabolic weight loss, such as AIDS and cancer cardiac wasting. In addition, they have been abused to improve muscle mass in sports doping. In cachectic ESRD, injections of rhGH induce a strong and sustained anabolic effect, as indicated by a positive nitrogen balance [117] . Also of interest are sex hormones, which have pleiotropic effects and may be important for atheroprotection as men with low testosterone levels as well as women with low estrogen levels are at increased risk of CVD. The reported ability of sex hormones to interfere with cytokine production by expression of IL-6 mRNA may contribute to these protective effects [118] .
Recombinant insulin-like growth factor (rhIGF-1) may induce an anabolic response in patients in whom the primary cause of malnutrition is a low protein intake. Indeed, injections of rhIGF-1 has been shown to induce a strong and sustained anabolic effect in PD patients [119] . However, the effectiveness of anabolic hormones, such as rhGH and rhIGF-1, has proved to be blunted if inflammation is present [120] . This again underlines the need to provide an integrated therapy for wasting in ESRD. Clearly, larger studies are needed to establish the respective role of anabolic hormones in inflamed and non-inflamed ESRD patients with wasting.
Other Drugs
A variety of other agents that are not commonly used in ESRD patients may also have a role in the treatment of inflammatory-associated wasting. There have been numerous reports suggesting that inhibition of prostaglandin production by non-steroidal anti-inflammatory drugs may impact tumormediated wasting [121] . However, as these drugs may have serious side effects in ESRD patients, such as bleeding from the gastrointestinal tract, increased risk of acute cardiovascular events, haematopoietic toxicities and reduced residual renal function, nephrologists have been reluctant to use them widely. However, COX-2 inhibitors also have been reported to reverse tumor-mediated wasting and associated humoral factors, such as IL-6 in different experimental models of cachexia [122] , and the potential of this new class of drug in reversing uremic wasting needs to be addressed in order for evaluate the risks and benefits (Fig. 1) .
Targeted anti-cytokine treatment strategies, which have been tested in patients with other inflammatory states, should also be considered for use in ESRD patients [22] .
CONCLUSIONS
Cachexia is a common clinical feature of ESRD that encompasses both anorexia and catabolism and seems to be associated with increased inflammatory activity as well as with cardiovascular disease. Cachexia in ESRD patients is multifactorial and, as such, single therapeutic strategies are not likely to be successful. Given the hitherto rather poor results of energy and protein supplementation, new treatment strategies are needed. We believe that much could be learned from other wasted and inflamed patients groups, such as those with HIV, CHF, and cancer, in which various antiinflammatory treatment strategies in combination with efforts to improve nutritional intake have led to improved nutritional status and outcome. With this goal in mind, we encourage further studies towards establishing an effective and safe integrated therapy against cachexia in ESRD, evaluating both traditional and non-traditional strategies.
